PMID- 15102867
OWN - NLM
STAT- MEDLINE
DCOM- 20041216
LR  - 20121115
IS  - 0091-2700 (Print)
IS  - 0091-2700 (Linking)
VI  - 44
IP  - 5
DP  - 2004 May
TI  - Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect 
      unfractionated heparin-regulated blood coagulation parameters.
PG  - 474-80
AB  - The objective of this study was to evaluate the potential for hemostatic 
      interaction between a full analgesic dose of parecoxib sodium (parecoxib), a 
      prodrug of the COX-2 specific inhibitor valdecoxib, and unfractionated heparin 
      (UFH) in healthy male subjects. This open-label, single-center study comprised 
      two treatment periods. In treatment period I, fasted, eligible subjects (n = 18) 
      received a UFH bolus (4000 U) followed by a 36-hour UFH infusion (start dose 
      10-14 U/kg). Activated partial thromboplastin time (aPTT), prothrombin time (PT), 
      and platelet counts were measured at regular intervals up to 24 hours after the 
      end of the UFH infusion. After a 2-day washout, patients randomized to treatment 
      period II received a full analgesic dosage of parecoxib 40 mg bid intravenously 
      (IV) for 6 days (n = 18), with concomitant UFH (same regimen as treatment period 
      I) on day 5 (n = 18). APTT, PT, and platelet counts were evaluated at regular 
      intervals up to 24 hours after UFH infusion. Coadministration of parecoxib 40 mg 
      bid IV with UFH (treatment period II) had no significant effect on aPTT, PT, or 
      platelet counts, which were similar to those of participants receiving UFH alone 
      (treatment period I) at all time points. These results show that a full analgesic 
      dose of parecoxib, a COX-2-specific inhibitor available for parenteral 
      administration, can be coadministered with UFH without affecting blood 
      coagulation parameters. Therefore, parecoxib may be administered to patients who 
      are receiving UFH for thromboprophylaxis.
FAU - Noveck, Robert J
AU  - Noveck RJ
AD  - Clinical Research Center, New Orleans, Louisiana, USA.
FAU - Hubbard, Richard C
AU  - Hubbard RC
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Isoenzymes)
RN  - 0 (Isoxazoles)
RN  - 0 (Membrane Proteins)
RN  - 9005-49-6 (Heparin)
RN  - 9TUW81Y3CE (parecoxib)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
SB  - IM
MH  - Adult
MH  - Blood Coagulation Factors
MH  - Cyclooxygenase 2
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Heparin/administration & dosage/*pharmacokinetics
MH  - Humans
MH  - Infusions, Intravenous
MH  - Isoenzymes/*antagonists & inhibitors/pharmacology
MH  - Isoxazoles/administration & dosage/adverse effects/*pharmacokinetics
MH  - Male
MH  - Membrane Proteins
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Platelet Count/methods
MH  - Prostaglandin-Endoperoxide Synthases/pharmacology
MH  - Prothrombin Time/methods
EDAT- 2004/04/23 05:00
MHDA- 2004/12/17 09:00
CRDT- 2004/04/23 05:00
PHST- 2004/04/23 05:00 [pubmed]
PHST- 2004/12/17 09:00 [medline]
PHST- 2004/04/23 05:00 [entrez]
AID - 44/5/474 [pii]
AID - 10.1177/0091270004264166 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2004 May;44(5):474-80. doi: 10.1177/0091270004264166.